

Table S2. Prevalence of neuropsychiatric symptoms, depression, anxiety, and median BAI, PHQ-9, and TDI scores at baseline among all study participants (including those lost to follow up).

Measure	Prevalence at Baseline, N=97 ^{1*}
Since COVID, do you now have more difficulty...	
Remembering conversations a few days later?	
Yes	25 (30%)
No	57 (70%)
Remembering placement of familiar objects?	
Yes	24 (29%)
No	57 (71%)
Finding the right words when speaking?	
Yes	40 (47%)
No	44 (53%)
Thinking clearly?	
Yes	28 (36%)
No	48 (64%)
Staying Focused?	
Yes	38 (48%)
No	41 (52%)
Since COVID, have you experienced...	
New or more frequent/severe headaches?	
Yes	25 (28%)
No	63 (72%)
Weakness in one or more parts of your body?	
Yes	23 (25%)
No	67 (75%)
Numbness or tingling?	
Yes	18 (20%)
No	72 (80%)
Changes in vision?	
Yes	19 (21%)
No	71 (79%)
Sense of dizziness, imbalance, or vertigo?	
Yes	26 (29%)
No	63 (71%)
Seizures?	
Yes	1 (1%)
No	89 (99%)
Beck Anxiety Inventory (BAI)	
No Anxiety	55 (67%)
Mild Anxiety	14 (17%)
Moderate Anxiety	9 (11%)
Severe Anxiety	4 (5%)
No response	15

PHQ-9	
No Depression	54 (59%)
Mild Depression	15 (15%)
Moderate Depression	8 (8%)
Moderately Severe Depression	9 (9%)
Severe Depression	5 (5%)
No response	6
Overall Median (IQR) Scores	
BAI	5 (2, 1)
PHQ-9	4 (1, 9)
TDI	24.75 (19.25, 27.75)
Threshold	5 (2, 7.5)
Discrimination	10 (8,11)
Identification	9 (7, 10)

¹ n (%); median (IQR).

*total participants reported for each symptom will not equate to 97 due to some participants choosing: (1) to not reply; or (2) "unsure".